January 2, 2024 10:59 AM EST
News Briefing

As­traZeneca's $40M deal with Al­lo­ri­on; Apol­lo rais­es $33M; Xo­ma's stock buy­back

Jaimy Lee

Deputy Editor

An­oth­er Chi­na-US deal for As­traZeneca: The British drug­mak­er is pay­ing $40 mil­lion up­front to Al­lo­ri­on Ther­a­peu­tics to de­vel­op the com­pa­ny’s L858R …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

A service from the Financial Times